SAN RAFAEL, Calif. and TORONTO, Nov. 17,
2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
(Nasdaq: BMRN) and Deep Genomics today announced that the companies
have entered into a preclinical collaboration that will use Deep
Genomics' artificial intelligence drug discovery platform (The AI
Workbench) to identify oligonucleotide drug candidates in four rare
disease indications with high unmet need. Deep Genomics will
receive an undisclosed upfront payment and is eligible to receive
development milestones as a part of the collaboration.
BioMarin will receive an exclusive option to obtain Deep Genomics'
rights to each program for development and commercialization. The
companies did not disclose financial terms.
In the collaboration, Deep Genomics will use its AI Workbench to
identify and validate target mechanisms and lead candidates, and
BioMarin will advance them into preclinical and clinical
development. The AI Workbench enables rapid exploration of novel
targetable mechanisms and therapeutic candidates. It combines
deep learning, automation, advanced biomedical knowledge and
massive amounts of in vitro and in vivo data to accurately identify
targetable molecular mechanisms and guide the discovery and
development of oligonucleotide therapies.
"We are thrilled to collaborate with Deep Genomics, a leader in
AI-facilitated discovery and development of potential
oligonucleotide-based therapeutics, and to tap into their AI
Workbench to unlock the potential of exciting new drug targets for
rare diseases," said Lon Cardon,
Chief Scientific Strategy Officer and Senior Vice President at
BioMarin. "We believe the combination of Deep Genomics'
experience in using artificial intelligence to creatively modulate
targets coupled with our proven track record in developing
transformational medicines for patients with rare diseases will
speed BioMarin's trajectory into new biological frontiers."
"We share BioMarin's pioneering spirit in drug discovery and are
delighted to partner with them," said Brendan Frey, Founder and Chief Executive
Officer of Deep Genomics. "Our second generation AI Workbench
continues to unlock a rapidly growing number of therapeutic
opportunities for patients with genetically defined
disorders. BioMarin is an industry leader in developing
transformational therapies for patients with rare diseases, and we
look forward to working with them to expand their clinical
pipeline."
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for serious and
life-threatening rare genetic diseases. The Company's portfolio
consists of six commercialized products and multiple clinical and
pre-clinical product candidates. For additional information, please
visit www.biomarin.com. Information on BioMarin's website is
not incorporated by reference into this press release.
About Deep Genomics
Deep Genomics is a therapeutics company founded on computational
biology and artificial intelligence. It's AI-based systems,
datasets, processes and culture enable the intentional design of
effective and highly safe genetic medicines with a speed and a
success rate that far exceed what was previously possible. The AI,
genome biology, software engineering and preclinical research team
is located in the heart of Toronto,
Canada, next to the AI research labs of Google, Uber, the
Vector Institute and the University of
Toronto, where deep learning was invented. The clinical and
business development teams are based in Boston, Massachusetts. For more
information, visit www.deepgenomics.com and follow us on
Twitter at @deepgenomics.
BioMarin® is a registered trademark of BioMarin Pharmaceutical
Inc.
Contacts:
|
|
Investors
|
Media
|
|
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
|
|
|
Michael
Lampe
|
|
Deep
Genomics
|
|
(484)
575-5040
|
|
michael@scientpr.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-and-deep-genomics-to-collaborate-on-advancing-programs-identified-using-artificial-intelligence-301174203.html
SOURCE BioMarin Pharmaceutical Inc.